All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Deucravacitinib in patients with moderate-to-severe scalp psoriasis: Results from the phase IIIb/IV PSORIATYK SCALP trial
|
The ongoing phase IIIb/IV multicenter, randomized, double-blind PSORIATYK SCALP trial (NCT05478499) is evaluating the safety and efficacy of deucravacitinib (n = 103), an oral, selective, allosteric TYK2 inhibitor, vs placebo (n = 47) in adult patients with moderate-to-severe scalp psoriasis.1 This trial includes patients with less extensive overall psoriasis (BSA involvement 3–10%) compared with the phase III POETYK PSO-1 and POETYK PSO-2 trials. Interim results were presented by Mark Lebwohl at the EADV 2024 Congress. 1 |
| Key learnings |
|
The primary endpoint was met; at Week 16, ss-PGA 0/1 response rates were 48.5% in the deucravacitinib group vs 13.7% in the placebo group (p < 0.0001). Among patients with sPGA ≥3, ss-PGA 0/1 response rates in the deucravacitinib (n = 96) vs placebo groups (n = 47) were 50.0% vs 12.8% (p < 0.0001). |
|
At Week 16, deucravacitinib when compared to placebo improved PSSI 90 response rates (38.8% vs 2.0%; p < 0.0001), CFB scalp-specific itch NRS (−3.2 vs −0.7; p < 0.0001), and sPGA 0/1 response rates in patients with sPGA ≥3 (51.0% vs 4.3%; p < 0.0001), BSA involvement 3–10% (42.9% vs 5.3%; p < 0.0001) and BSA involvement >10% (57.6% vs 0.0%; p = 0.0004). |
|
Safety findings were consistent with the known profile of deucravacitinib, with no new signals observed. |
|
Results from the PSORIATYK SCALP trial suggest that deucravacitinib is well tolerated and effective in patients with moderate-to-severe scalp psoriasis, including patients with less extensive overall body psoriasis. |
Abbreviations: BSA, body surface area; CFB, change from baseline; EADV, European Academy of Dermatology and Venereology; NRS, numeric rating scale; PSSI 90, ≥90% improvement from baseline in Psoriasis Scalp Severity Index; sPGA, static Physician Global Assessment; sPGA 0/1; sPGA score of 0 or 1; ss-PGA 0/1, scalp-specific Physician Global Assessment score of 0 or 1; TYK2, tyrosine kinase 2.
- Lebwohl M. Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: efficacy and safety results of a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP). Oral Abstract #FC04.07. Presented at: European Academy of Dermatology and Venereology Congress; Sep 25–28, 2024; Amsterdam, NL.
Your opinion matters
4 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox